These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34347737)
1. Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. Caron B; Reimund JM; Ben Abdelghani M; Sondag D; Noirclerc M; Duclos B; Kurtz JE; Nguimpi-Tambou M Pancreas; 2021 Jul; 50(6):803-806. PubMed ID: 34347737 [TBL] [Abstract][Full Text] [Related]
2. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170 [TBL] [Abstract][Full Text] [Related]
3. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981 [TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727 [TBL] [Abstract][Full Text] [Related]
5. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222 [TBL] [Abstract][Full Text] [Related]
7. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383 [TBL] [Abstract][Full Text] [Related]
8. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386 [TBL] [Abstract][Full Text] [Related]
9. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
10. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375 [TBL] [Abstract][Full Text] [Related]
11. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Lorgis V; Chauffert B; Gentil J; Ghiringhelli F Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963 [TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Wu AA; Bever KM; Ho WJ; Fertig EJ; Niu N; Zheng L; Parkinson RM; Durham JN; Onners B; Ferguson AK; Wilt C; Ko AH; Wang-Gillam A; Laheru DA; Anders RA; Thompson ED; Sugar EA; Jaffee EM; Le DT Clin Cancer Res; 2020 Oct; 26(19):5129-5139. PubMed ID: 32591464 [TBL] [Abstract][Full Text] [Related]
14. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620 [TBL] [Abstract][Full Text] [Related]
15. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770 [TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ; N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching. Mie T; Sasaki T; Takeda T; Fukuda K; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N Pancreas; 2021 Apr; 50(4):595-601. PubMed ID: 33939674 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639 [TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349 [No Abstract] [Full Text] [Related]
20. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]